Vor Biopharma Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; filed March 23, 2023. This is an annual report, not a standalone fourth-quarter financial statement. Vor is a clinical-stage cell and genome engineering company developing engineered hematopoietic stem cells and targeted therapies for blood cancers, initially AML.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $64.6 million | $47.5 million |
| General and administrative expense | $28.9 million | $21.5 million |
| Total operating expenses | $93.4 million | $69.0 million |
| Net loss | $92.1 million | $68.9 million |
| Basic and diluted loss per share | $2.33 | $2.10 |
| Net cash used in operating activities | $85.1 million | $69.1 million |
- No product revenue or operating profit; margins are not meaningful for this pre-commercial company. Interest income was $1.3 million, versus $0.1 million in 2021.
- At December 31, 2022, cash and cash equivalents were $57.7 million and marketable securities were $172.5 million, totaling $230.2 million. Current assets were $237.0 million and current liabilities were $13.1 million.
- Operating cash use increased by $16.0 million year over year, primarily reflecting higher staffing, facility and clinical/manufacturing spending. Investing cash use was $94.1 million, including $8.5 million in property and equipment; financing provided $117.1 million.
- No borrowings are reported. Operating lease liabilities totaled $38.9 million, including $3.3 million current and $35.6 million non-current.
- Management estimated year-end cash, cash equivalents and marketable securities would fund operating expenses and capital needs into the first quarter of 2025, subject to assumptions and possible changes in the operating plan. Additional capital will be required.
Material changes versus 2021
- Net loss widened by $23.2 million, while operating expenses rose $24.4 million. R&D increased $17.0 million and G&A increased $7.4 million.
- R&D growth reflected $9.3 million higher personnel expense, $5.6 million higher facility costs associated with laboratory and cGMP manufacturing expansion, and $2.2 million higher clinical, manufacturing and consulting expense.
- Operating cash use rose from $69.1 million to $85.1 million. Cash and cash equivalents fell to $57.7 million from $119.8 million, while marketable securities rose to $172.5 million from $87.7 million.
- In December 2022, Vor raised net proceeds of $61.3 million in a public offering and $49.5 million in a concurrent private placement. Common shares outstanding increased to 66.0 million from 37.2 million at year-end 2021.
Business progress, outlook and key risks
- Trem-cel: The Phase 1/2a VBP101 trial is evaluating transplant feasibility, tolerability and engraftment, followed by Mylotarg treatment. Initial data in two patients showed engraftment and blood-cell recovery. In the first patient, neutrophil and platelet counts were maintained through three sequential Mylotarg doses; however, detectable measurable residual disease led to other therapies, and the patient subsequently relapsed. The trial is not designed to establish combination efficacy.
- VCAR33 programs: VCAR33 AUTO is being studied in an NMDP-sponsored Phase 1/2 trial; Vor does not control that trial or its data-release timing. Vor planned to submit an IND for VCAR33 ALLO in the first half of 2023. The company planned to report additional VBP101 data by year-end 2023.
- Development strategy: Vor aims to pair trem-cel with CD33-directed therapies, including VCAR33 ALLO, and is researching other targets and multiplex-edited approaches. Its Cambridge clinical manufacturing facility began operations in 2022, but the company still relies on third parties for materials and some manufacturing and has no long-term agreements with many suppliers.
- Key risks: The platform is novel and not clinically validated; evidence is limited to early development and very small patient numbers. Clinical, regulatory, manufacturing, donor-identification, safety, intellectual-property and reimbursement outcomes remain uncertain. Vor has incurred substantial losses, has no product-sales history, expects losses to continue and may need to reduce or delay programs if additional financing is unavailable.
- Contingencies and controls: Vor reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal controls because of the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Whether larger and longer-term VBP101 results confirm engraftment, durable hematologic protection, safety and any clinical benefit; note the first patient relapsed.
- Whether the VCAR33 ALLO IND was submitted and the trial initiated, and whether NMDP releases meaningful VCAR33 AUTO results.
- Whether the stated cash runway to Q1 2025 remains valid given the pace of spending, clinical plans and manufacturing costs, and whether further financing will be needed.
- How share issuance, including ATM sales and equity compensation, affects dilution and the company’s capital needs.
- Whether in-house manufacturing can reliably support clinical programs and whether key third-party supply, licensing and intellectual-property risks are resolved.